Sino Biopharmaceutical Limited Stock Annual Yield
SBMFF Stock | USD 0.42 0.01 2.33% |
Sino Biopharmaceutical Limited fundamentals help investors to digest information that contributes to Sino Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Sino Pink Sheet. The fundamental analysis module provides a way to measure Sino Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sino Biopharmaceutica pink sheet.
Sino |
Sino Biopharmaceutical Limited Company Annual Yield Analysis
Sino Biopharmaceutica's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Current Sino Biopharmaceutica Annual Yield | 0.03 % |
Most of Sino Biopharmaceutica's fundamental indicators, such as Annual Yield, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sino Biopharmaceutical Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
Competition |
In accordance with the recently published financial statements, Sino Biopharmaceutical Limited has an Annual Yield of 0.0278%. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The annual yield for all United States stocks is notably lower than that of the firm.
Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
All Next | Launch Module |
Sino Fundamentals
Return On Equity | 0.29 | |||
Return On Asset | 0.0451 | |||
Profit Margin | 0.29 % | |||
Operating Margin | 0.16 % | |||
Current Valuation | 10.34 B | |||
Shares Outstanding | 18.81 B | |||
Shares Owned By Insiders | 47.86 % | |||
Shares Owned By Institutions | 14.86 % | |||
Price To Earning | 24.17 X | |||
Price To Book | 2.51 X | |||
Price To Sales | 0.41 X | |||
Revenue | 26.86 B | |||
Gross Profit | 21.53 B | |||
EBITDA | 19.87 B | |||
Net Income | 14.61 B | |||
Cash And Equivalents | 15.67 B | |||
Cash Per Share | 0.85 X | |||
Total Debt | 5.21 B | |||
Debt To Equity | 0.31 % | |||
Current Ratio | 1.55 X | |||
Book Value Per Share | 1.64 X | |||
Cash Flow From Operations | 5.37 B | |||
Earnings Per Share | 0.06 X | |||
Price To Earnings To Growth | 0.53 X | |||
Number Of Employees | 25.55 K | |||
Beta | 0.51 | |||
Market Capitalization | 10.91 B | |||
Total Asset | 60.54 B | |||
Working Capital | 6 B | |||
Current Asset | 13.73 B | |||
Current Liabilities | 7.73 B | |||
Z Score | 1.2 | |||
Annual Yield | 0.03 % | |||
Five Year Return | 0.74 % | |||
Net Asset | 60.54 B | |||
Last Dividend Paid | 0.083 |
About Sino Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sino Biopharmaceutical Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sino Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sino Biopharmaceutical Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sino Pink Sheet
Sino Biopharmaceutica financial ratios help investors to determine whether Sino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sino with respect to the benefits of owning Sino Biopharmaceutica security.